CD22 and neoplasm: The three tumor-targeting proteins that were tested were single-chain variable fragment (scFv) variants of the full-length antibodies of an in-house screened anti-B7-H3,19 inotuzumab, a clinically approved CD22 binder,20,21 and the well-characterized HER2-binding trastuzumab.22